Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics - ScienceDirect
PDF) Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience
Complement activation and the mechanism of action of Eculizumab. The AP... | Download Scientific Diagram
What's New in the Treatment of Atypical Hemolytic Uremic Syndrome? (Transcript)
Soliris® (eculizumab) HCP | Mechanism of Action
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document | Nefrología
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study - EClinicalMedicine
Eculizumab | Nature Reviews Drug Discovery
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab | SpringerLink
The use of Eculizumab in transplantation: What's new? - Renal Fellow Network
Figure 1 from Eculizumab: A Review in Generalized Myasthenia Gravis | Semantic Scholar
An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document | Nefrología
Toxins | Free Full-Text | Monoclonal Antibody Therapy and Renal Transplantation: Focus on Adverse Effects | HTML
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience
Akari Therapeutics - Set up to compete in the Soliris market and more | Edison
Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder | SpringerLink
Paroxysmal nocturnal hemoglobinuria revisited: news on pathophysiology, clinical course and treatment
Soliris® (eculizumab) HCP | Mechanism of Action
A Preliminary Update to The Soliris To Stop Immune Mediated Death in Covid-19 (SOLID-C19) Compassionate Use Study. - Hudson Medical + Wellness
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria | Nature Biotechnology
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
Eculizumab: the molecule. The structure of the anti-complement 5... | Download Scientific Diagram
ULTOMIRIS® (ravulizumab-cwvz) | About ULTOMIRIS
